Skip to main content
SpringerLink
Log in

The ASCO 2018 annual meeting: update on the adjuvant treatment of early breast cancer

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

At this year’s American Society of Clinical Oncology (ASCO) annual meeting two large phase 3 trials, the ABCSG-18 and the D‑CARE study, analysed the effects of adjuvant denosumab in breast cancer patients and reported different outcomes. Another phase 3 study, the ASTRRA trial, investigated the use of adjuvant ovarian function suppression (OFS) in high-risk premenopausal patients. This trial confirmed the benefit of OFS similar to the results of the already published SOFT/TEXT trials but raises some crucial questions on the optimal duration of OFS in these patients. The results of the SOFT/TEXT trials were also updated at this meeting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Early Breast Cancer Trialists’ Collaborative Group. (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353–61. https://doi.org/10.1016/S0140-6736(15)60908-4.

    Article  Google Scholar 

  2. Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of Adjuvant Bisphosphonates and other Bone-modifying agents in breast cancer: a cancer care ontario and American society of clinical oncology clinical practice guideline. J Clin Oncol. 2017;35(18):2062–81. https://doi.org/10.1200/JCO.2016.70.7257.

    Article  PubMed  Google Scholar 

  3. Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. J Clin Oncol. 2018;36(15_suppl):500–500. https://doi.org/10.1200/JCO.2018.36.15_suppl.500.

    Article  Google Scholar 

  4. Coleman RE, Finkelstein D, Barrios CH, et al. Adjuvant denosumab in early breast cancer: first results from the international multicenter randomized phase III placebo controlled D‑CARE study. J Clin Oncol. 2018;36(15_suppl):501–501. https://doi.org/10.1200/JCO.2018.36.15_suppl.501.

    Article  Google Scholar 

  5. Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:433–43. https://doi.org/10.1016/s0140-6736(15)60995-3.

    Article  CAS  PubMed  Google Scholar 

  6. Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with ovarian suppression in Premenopausal breast cancer. N Engl J Med. 2014;371:107–18. https://doi.org/10.1056/NEJMoa1404037.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in Premenopausal breast cancer. N Engl J Med. 2015;372:436–46. https://doi.org/10.1056/NEJMoa1412379.

    Article  CAS  PubMed  Google Scholar 

  8. Regan MM, Francis PA, Pagani O, et al. Absolute benefit of Adjuvant endocrine therapies for Premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2‑negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34:2221–31. https://doi.org/10.1200/JCO.2015.64.3171.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Francis PA, Pagani O, Fleming GF, et al. Tailoring Adjuvant endocrine therapy for Premenopausal breast cancer. N Engl J Med. 2018;379:122–37. https://doi.org/10.1056/NEJMoa1803164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Regan MM, Francis PA, Pagani O, et al. Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) her2-negative breast cancer (BC): results from TEXT and SOFT. J Clin Oncol. 2018;36(15_suppl):503–503. https://doi.org/10.1200/JCO.2018.36.15_suppl.503.

    Article  Google Scholar 

  11. Noh WC, Lee JW, Nam SJ, et al. Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: the ASTRRA study. J Clin Oncol. 2018;36(15_suppl):502–502. https://doi.org/10.1200/JCO.2018.36.15_suppl.502.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie, Ordensklinikum Linz Barmherzige Schwestern, Seilerstätte 4, 4010, Linz, Austria

    Clemens Dormann &  Karl J. Aichberger

Authors
  1. Clemens Dormann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karl J. Aichberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clemens Dormann.

Ethics declarations

Conflict of interest

C. Dormann and K.J. Aichberger declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dormann, C., J. Aichberger, K. The ASCO 2018 annual meeting: update on the adjuvant treatment of early breast cancer. memo 11, 272–275 (2018). https://doi.org/10.1007/s12254-018-0448-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-018-0448-3

Keywords

Search

Navigation